{
  "doc_id": "rak-watrobowokomorkowy-podsumowanie-zalecen",
  "created_date": "unknown_year",
  "country": "PO",
  "source_type": "clinical_guideline",
  "chunks": [
    {
      "heading": "",
      "text": "GUIDELINES DIAGNOSTIC-TERAPEUTIC PROCEDURE IN THE PHYSICAL PHYSICAL MOBILE-COMMODATION SUMMARY Recommendation Power of recommendation* 1. Primary prophylaxis 1.1 As part of primary prophylaxis of hepatocellular carcinoma, it is recommended that II, A vaccination against hepatitis B of all neonates and persons of increased risk groups 1.2 In all neonates of mothers infected with hepatitis B II virus, A it is recommended to administer the first vaccine and immunoglobulin against hepatitis B virus up to 48 hours after birth. 1.3 It is important to avoid risk factors by spreading knowledge of the roads II, A transmission of hepatitis II virus infections and their prevention capabilities, dissemination of follow-up awareness and implementation of rules to prevent chronic alcohol abuse, encouraging lifestyle modification to prevent obesity, metabolic syndrome and metabolic hepatic steatosis. 1.4 Preventive importance for the development of hepatocellular carcinoma has II, and eradication of hepatitis C virus infection and any other etiology-specific treatments resulting from liver inflammatory activity inhibition, however,",
      "start_page": 1,
      "end_page": 6
    },
    {
      "heading": "table under heading <none>",
      "text": "Row 1: Recommendation* Row 2: 1. Primary prophylaxis.Row 3: 1.1 As part of primary prophylaxis of hepatocellular cancer, vaccination against hepatitis B is recommended for all neonates and individuals at increased risk.II, A Row 5: 1.3 It is important to avoid risk factors by spreading knowledge about the routes of transmission and prevention of hepatitis virus infections, raising awareness of the consequences and implementing rules to prevent chronic abuse of alcohol, encouraging lifestyle modification to prevent obesity, metabolic syndrome and hepatic steatosis.II, A Row 6: 1.4 Preventive importance for the development of hepatocellular carcinoma has eradication of hepatitis C infection and any other specific etiological treatment resulting in inhibition of hepatic inflammatory activity, but during a period of time.",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "table under heading <none>",
      "text": "Row 1: direct-acting antivirals The risk of hepatocellular carcinoma is significantly re-duced but does not disappear in such patients, therefore it is recommended to continue ultrasonographic surveillance.Row 2: 2.8 In case of detection during standard ultrasound surveillance of liver lesions < 1 cm in diameter, it is recommended to increase surveillance for 2 years (USG ultrasonography at intervals of 3 months).IV, A Row 3: 2.9 In case of detection during standard ultrasound surveillance of liver lesions with a diameter > 1 cm or nodule size increase during intensified surveillance, it is recommended to perform a high-quality contrasting imaging study (4-phase computer tomography or dynamic magnetic resonance).",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "table under heading <none>",
      "text": "Row 1: 4.2.2. in case of an ultrasound finding of focal lesions > 1 cm by diagnostic method, multiphasic computer tomography or magnetic resonance imaging; 4.2.3. in case of changes > 1 cm typical radiographic image based on: (1) arterial enhancement phenomenon (wash-in) and (2) a later phase washing (wash-out) enables diagnosis of hepatocellular carcinoma; 4.2.4. in case only one of the criteria for diagnosis of hepatocellular carcinoma (wash-in or wash-out) is met, but at the same time at least one additional characteristic suggestive of malignant nature of the lesion (tab. 3) a change with a high risk of cancer, which requires rapid control (approximately 3 months), to be discussed at a multi-disciplinary meeting or biopsy.",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "table under heading <none>",
      "text": "Row 1: 6.4. Patients should be discussed in multi-specialized teams to take into account all changes in clinical status and adapt dynamically to individualised treatment options.III,A Row 2: 6.5. The assessment of response to treatment in hepatocellular carcinoma should be based on the RECIST criteria for locoregional therapy. In the case of systemic therapies, mRECIST or RECIST 1.1 systems are recommended to use changes in serum biomarker concentrations to evaluate response to treatment is in the course of testing and cannot be routinely recommended.II, A II, B Row 3: 6.6. For the evaluation of response after resection, locoregional or systemic therapy, multiphasic testing is recommended- not tomography of computer or magnetic resonance with contrast.II, B Row 4: 7. Surgical treatment",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "table under heading <none>",
      "text": "Row 1: used on the basis of prospective results of the study according to the mRECIST criteria.Row 2: 7.2.5. Transplantation of a liver fragment from a live donor may be an alternative in patients with an expected longer than 6 months waiting period; it is possible in such cases to liberalize the Milan criteria according to the experience of the centre.",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "table under heading <none> (column 2)",
      "text": "Row 1: Row 2: III, B",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "table under heading <none> (column 2)",
      "text": "Row 1: II, A Row 2: I, A Row 3: I, A Row 4: I, A Row 5: III, A Row 6: I, A Row 7: III, A Row 8: III, A Row 9: II, A Row 10: II, B",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "table under heading <none> (column 2)",
      "text": "Row 1: I, A Row 2: I, A Row 3: III, B Row 4: I, B",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "table under heading <none>",
      "text": "Row 1: with changes in two liver lobes or with relapsed disease, a greater benefit can potentially be gained from the use of chemoembolization with doxorubicin particles than conventional arterial chemo-embolization.Row 2: 8.2.5. In selected cases, after two inefficient arterial chemo-embolization procedures, consideration can be given to performing a third procedure.III,B Row 3: 8.2.6. It is not recommended to combine pre-arterial chemoembolization with sorafenib.I, A Row 4: 8.2.7. Radioembolization can be used instead of trans-arterial chemoembolization as a bridge therapy for liver transplantation, providing longer time for progression.I, A Row 5: 8.2.8. Radioembolisation can be safely used in patients with Child and Pugh â‰¤ B7 hepatic function.",
      "start_page": 6,
      "end_page": 6
    }
  ]
}